Research map: Viewpoint: Pathway-Sensitive Eligibility for Biologic Therapy in COPD: The Role of Primary Care, Phenotyping, and Eosinophil-Guided Management

Back to the article

Papers in this map

  1. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease · Ian Douglas Pavord · 2017 · 626 citations · Cited by this paper
  2. Immunosuppressive medication patterns in rheumatoid arthritis–associated interstitial lung disease by antifibrotic documentation status: A multicenter U.S. electronic health record study · 2026 · Related
  3. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts · Surya Prakash Bhatt · 2023 · 521 citations · Cited by this paper
  4. Neuromuscular junction biomarker CAF22 predicts functional decline in patients with chronic obstructive pulmonary disease · 2026 · Related
  5. Airway inflammation in COPD: progress to precision medicine · Christopher Edward Brightling · 2019 · 432 citations · Cited by this paper
  6. Adults with congenital lung malformations: A descriptive analysis of an underexplored population · 2026 · Related
  7. Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease · Nermin Diab · 2018 · 332 citations · Cited by this paper
  8. Use of dual targeting during volume control ventilation is associated with increased delivery of non-lung-protective tidal volumes · 2026 · Related
  9. Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease · Leena George · 2015 · 331 citations · Cited by this paper
  10. Step-DAWN: an Italian algorithm proposed for the management of inhaled corticosteroids in severe asthma · 2026 · Related
  11. Underreporting Exacerbation of Chronic Obstructive Pulmonary Disease in a Longitudinal Cohort · Lisa Langsetmo · 2007 · 329 citations · Cited by this paper
  12. Phenotypic patterns and outcomes of connective tissue disease-associated pulmonary arterial hypertension: a Saudi single center experience · 2026 · Related
  13. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation · Surya Prakash Bhatt · 2024 · 295 citations · Cited by this paper
  14. Sex-based differences in long-term respiratory and pulmonary vascular outcomes after acute pulmonary embolism: A propensity-matched analysis of 795,338 patients · 2026 · Related
  15. Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative for Chronic Obstructive Lung Disease Science Committee 2022 Review · Dave Singh · 2022 · 163 citations · Cited by this paper
  16. Rheumatoid arthritis-associated interstitial lung disease: Pathogenesis, risk stratification, and management · 2026 · Related
  17. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype · Frank C. Sciurba · 2025 · 160 citations · Cited by this paper
  18. Oxidative Stress–Driven Dysregulation of the MMP-2/TIMP-2 Axis in Chronic Obstructive Pulmonary Disease: Molecular Mechanisms, Genetic Polymorphisms, and Therapeutic Implications · 2026 · Related
  19. Stability of Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts · Olorunfemi A. Oshagbemi · 2017 · 135 citations · Cited by this paper
  20. Smoking cessation and depression risk in newly diagnosed COPD patients: A nationwide cohort study · 2026 · Related
  21. What does endotyping mean for treatment in chronic obstructive pulmonary disease? · Alvar G.N. Agustí · 2017 · 99 citations · Cited by this paper
  22. The stability of blood Eosinophils in chronic obstructive pulmonary disease · Gabriella Long · 2020 · 53 citations · Cited by this paper
  23. The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD · Bartolomé R. Celli · 2024 · 26 citations · Cited by this paper
  24. Blood Eosinophil Count Stability in Chronic Obstructive Pulmonary Disease and the Eosinophilic Exacerbator Phenotype · Federico Baraldi · 2025 · 23 citations · Cited by this paper
  25. Inflammation and infections in unreported chronic obstructive pulmonary disease exacerbations · Maria Adelaide Calderazzo · 2019 · 16 citations · Cited by this paper
  26. Determining the influence of the primary and specialist network of care on patient and system outcomes among patients with a new diagnosis of chronic obstructive pulmonary disease (COPD) · Joan E. Tranmer · 2022 · 15 citations · Cited by this paper
  27. Real-World Treatment Patterns and Switching Following Moderate/Severe Chronic Obstructive Pulmonary Disease Exacerbation in Patients with Commercial or Medicare Insurance in the United States · Michael Bogart · 2023 · 11 citations · Cited by this paper
  28. Εosinophilic Chronic Obstructive Pulmonary Disease. What Do We Know So Far? · Κonstantinos Bartziokas · 2024 · 6 citations · Cited by this paper
  29. How many blood eosinophil measurements are needed to identify COPD patients eligible for biologic therapy? A multi-source decision analysis simulation · Pier‐Valerio Mari · 2026 · 4 citations · Cited by this paper
  30. Stability of blood eosinophils during acute exacerbations in patients with chronic obstructive pulmonary disease · Qidong Chen · 2025 · 3 citations · Cited by this paper
  31. Adherence to the Chronic Obstructive Pulmonary Disease guidelines in primary care: The Greek COPD COCARE study · Ioanna Tsiligianni · 2025 · 2 citations · Cited by this paper
  32. Eligibility for biological treatments in COPD patients experiencing a severe COPD exacerbation · Stavroula Zaneli · 2026 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)